Assessment of molecular heterogeneity in tumor is a challenging task. It is for the first time Palanisamy et al have demonstrated the existence of rare subset of prostate cancer with heterogeneous molecular aberrations involving ETS family genes and SPINK1 expression utilizing both standard immunohistochemistry (IHC) and RNA in situ hybridization (Advanced Cell Diagnostics RNAscope® Technology). The presenter will discuss the application of RNA ISH technology to reveal hitherto unidentified molecular subtypes of prostate cancer.
1. Kunju LP, Carskadon S, Siddiqui J, Tomlins SA, Chinnaiyan AM, Palanisamy N.(2014) Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol. 2014 Sep;22(8):e32-40. doi: 10.1097/PAI.0000000000000095.
2. Joshua I Warrick, Scott A Tomlins, Shannon L Carskadon, Allison M Young,Javed Siddiqui, John T Wei, Arul M Chinnaiyan, Lakshmi P Kunju, and Nallasivam Palanisamy Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization— a correlative study with urine PCA3 and TMPRSS2-ERG Modern Pathology (2014) 27, 609–620
Cancer researchers, pathologists, histologists interested in understanding new molecular techniques to:
- Uncover intra-tumoral heterogeneity
- Understand how measuring RNA expression can uncover details of tumor microenvironments
- Understand cell-specific expression information
- Visualize RNA targets in the full context of tissue architecture and/or measure regional RNA distribution
- Quantify expression of coding and non-coding RNA including pseudogenes
- How RNAscope Technology can be used in cancer research
- How RNAscope Technology delivers quantitative molecular detection and morphological context in a single assay
- Ease of using the highly sensitive and specific assay for virtually any gene in any tissue
- Advantages of RNAscope Technology versus other ISH and IHC methods